ENLON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ENLON (ENLON).
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
| Metabolism | Enzymatic hydrolysis by plasma esterases, primarily butyrylcholinesterase (pseudocholinesterase); minor hepatic metabolism. |
| Excretion | Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%) |
| Half-life | Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients |
| Protein binding | Minimal protein binding (<5%) |
| Volume of Distribution | 0.7-1.4 L/kg; indicates distribution into total body water and extracellular fluid; may be increased in neonates and decreased in elderly |
| Bioavailability | Intramuscular: 75-100%; Subcutaneous: 80-100%; Oral: <5% due to extensive first-pass metabolism |
| Onset of Action | Intravenous: <30 seconds; Intramuscular: 2-5 minutes; Subcutaneous: 2-10 minutes |
| Duration of Action | Intravenous: 5-10 minutes; Intramuscular: 10-30 minutes; Subcutaneous: 20-60 minutes; duration may be extended by anticholinesterases |
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use due to prolonged clearance. |
| Liver impairment | Child-Pugh B or C: reduce dose by 50% and monitor neuromuscular function closely. |
| Pediatric use | Children >1 month: 0.2 mg/kg IV over 15-30 seconds; may repeat every 5-10 minutes as needed. |
| Geriatric use | Elderly patients: use lower initial doses (0.1 mg/kg IV) and titrate carefully due to reduced renal and hepatic function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ENLON (ENLON).
| Breastfeeding | Excretion into breast milk is unknown due to quaternary structure limiting passage. M/P ratio not established. Caution: potential for infant cholinergic effects (e.g., diarrhea, weakness). Consider benefit of treatment of myasthenia gravis versus risk; avoid prolonged high doses. |
| Teratogenic Risk | Edrophonium (Enlon) is a quaternary ammonium compound; placental transfer is limited. No adequate studies in pregnant women. Animal reproduction studies not available. First trimester: theoretical risk of fetal bradycardia if significant maternal absorption; use only if clearly needed. Second/third trimesters: can cause transient fetal bradycardia and uterine hypertonus; reserve for life-threatening myasthenic crisis. Overall, FDA Pregnancy Category C. |
■ FDA Black Box Warning
Not recommended for use in newborns due to increased risk of prolonged neuromuscular blockade and respiratory complications.
| Serious Effects |
Hypersensitivity to enlon or other bisquaternary ammonium compounds; known reduced plasma cholinesterase activity (e.g., genetic deficiency, severe liver disease, advanced age, pregnancy).
| Precautions | Risk of prolonged neuromuscular blockade, especially in patients with reduced plasma cholinesterase activity, renal impairment, or hepatic disease; monitor with peripheral nerve stimulator; have resuscitation equipment available. |
| Food/Dietary | No known significant food interactions with edrophonium. However, avoid large meals immediately before the test as gastric distention may interfere with assessment. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, respiratory function, and signs of cholinergic crisis (excessive salivation, sweating, bradycardia). Fetal monitoring: assess fetal heart rate for bradycardia during administration, especially in third trimester. Observe newborn for transient myasthenic or cholinergic symptoms. |
| Fertility Effects | No known adverse effects on fertility in animal studies; human data lacking. Theoretical: cholinergic modulation might affect uterine receptivity, but no reports. |
| Clinical Pearls | Enlon (edrophonium) is a short-acting acetylcholinesterase inhibitor used for diagnosis of myasthenia gravis. Administer atropine at bedside to counteract severe cholinergic side effects. Monitor for bradycardia, hypotension, and bronchospasm. Test interpretation: improvement in muscle strength within 30-60 seconds supports MG diagnosis. Avoid in patients with mechanical obstruction of GI or urinary tract. |
| Patient Advice | Inform your doctor if you have asthma, heart problems, or urinary obstruction. · You may experience increased salivation, sweating, or tearing during the test. · Notify the nurse immediately if you feel faint, have difficulty breathing, or chest discomfort. · The test is brief; effects last only a few minutes. · Do not eat or drink for 2 hours before the test. |